Nutriband ups credit line pre-FDA fentanyl product application

 Company targeting FDA submission in the first half of 2024

AVERSA™ Fentanyl is the flagship product of the Company's AVERSA™ Platform

Nutriband Inc. ("Company") (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it has expanded its existing Credit Line facility to $5 Million USD to fund the continued development and regulatory submission process for the Company's patented lead product platform, AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system. The Company is targeting FDA submission for AVERSA™ Fentanyl in the first half of 2024. AVERSA Fentanyl is the flagship product of the Company's AVERSA™ Platform.

AVERSA™ Fentanyl combines Nutriband's proprietary AVERSA™ abuse-deterrent transdermal technology and Kindeva Drug Delivery's FDA-approved transdermal fentanyl patch system. AVERSA™ Fentanyl was recently estimated to have the potential to reach peak annual US sales of $80M - $200M.

https://finance.yahoo.com/news/nutriband-increases-existing-credit-line-132000185.html